Arrowstreet Capital’s Harvard Bioscience HBIO Stock Holding History

Arrowstreet Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7,703	Closed	-$478K	–	1309
2022 Q1	$478K	Sell	7,703 -11,252	-59%	-$666K	﹤0.01%	1033
2021 Q4	$1.34M	Sell	18,955 -2,807	-13%	-$200K	﹤0.01%	1101
2021 Q3	$1.52M	Sell	21,762 -11,682	-35%	-$930K	﹤0.01%	1199
2021 Q2	$2.79M	Buy	33,444 +13,947	+72%	+$987K	﹤0.01%	1248
2021 Q1	$1.06M	Sell	19,497 -440	-2%	-$21.4K	﹤0.01%	1765
2020 Q4	$855K	Hold	19,937	–	–	﹤0.01%	1870
2020 Q3	$600K	Buy	19,937 +13,686	+219%	+$460K	﹤0.01%	1973
2020 Q2	$194K	Buy	6,251 +4,121	+193%	+$111K	﹤0.01%	2175
2020 Q1	$47K	Hold	2,130	–	–	﹤0.01%	1822
2019 Q4	$65K	Hold	2,130	–	–	﹤0.01%	1687
2019 Q3	$65K	Buy	+2,130	New	+$52.9K	﹤0.01%	1518
2019 Q2	–	Sell	-3,149	Closed	-$136K	–	1509
2019 Q1	$136K	Sell	3,149 -801	-20%	-$29K	﹤0.01%	1668
2018 Q4	$126K	Hold	3,950	–	–	﹤0.01%	1288
2018 Q3	$207K	Buy	3,950 +1,430	+57%	+$80.3K	﹤0.01%	1018
2018 Q2	$135K	Hold	2,520	–	–	﹤0.01%	1024
2018 Q1	$126K	Buy	+2,520	New	+$113K	﹤0.01%	1078

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital's HBIO Position: Q2 2022 in Review

Arrowstreet Capital sold out of Harvard Bioscience (HBIO) in Q2 2022, closing a stake of 7,703 shares — an estimated $478K sold.

Arrowstreet Capital first reported a position in HBIO in Q1 2018 and held it in 16 quarters. The position peaked at $2.79M in Q2 2021. 90 funds tracked by Wall St. Rank hold HBIO as of Q2 2022.

Arrowstreet Capital reported no remaining Harvard Bioscience position as of Q2 2022 after selling out during the quarter.
Arrowstreet Capital sold 7,703 Harvard Bioscience shares in Q2 2022, an estimated $478K.
Arrowstreet Capital first reported a position in Harvard Bioscience in Q1 2018 and held it in 16 quarters.
Arrowstreet Capital's Harvard Bioscience position peaked at $2.79M in Q2 2021.
90 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2022.

Based on Arrowstreet Capital's 13F filing for Q2 2022, filed 15 Aug 2022.